IL17A and myeloid sarcoma: Two therapeutic RNA aptamers targeting interleukin-17 (IL-17) and midkine (a heparin-binding growth factor) have both shown reduced inflammation in the experimental autoimmune encephalitis mouse model which resembles MS [120–122].